Showing results (51-60 of 124) with videos related to

Sort By:
Pageof 13
Ultrasound in Medicine & Biology|June 9, 2004
Abnormally high resistive index of central retinal artery by ultrasound color Doppler in patients with viral chronic liver disease: correlation with worsening liver stagingPaolo Sorrentino, Giovanni Tarantino, Paolo Conca, et al.
Journal of Clinical Medicine|September 25, 2019
Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD?Giovanni Tarantino, Vincenzo Citro, Paolo Conforti, et al.
Journal of Gastroenterology and Hepatology|February 7, 2018
Prediction of carotid intima-media thickness in obese patients with low prevalence of comorbidities by serum copper bioavailabilityGiovanni Tarantino, Cristiana Porcu, Mario Arciello, et al.
Nutrients|November 25, 2023
The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and ProgressionValerio Caputo, Giovanni Tarantino, Silvano Junior Santini, et al.
Internal and Emergency Medicine|July 25, 2023
Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?Giovanni Tarantino, Gaia Sinatti, Vincenzo Citro, et al.
Nutrition & Metabolism|February 12, 2022
Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damageSilvano Junior Santini, Giovanni Tarantino, Antonella Iezzi, et al.
Ageing Research Reviews|June 15, 2013
Should visceral fat be reduced to increase longevity?Carmine Finelli, Luigi Sommella, Saverio Gioia, et al.
Metabolism: Clinical and Experimental|November 6, 2021
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver diseaseChander K Negi, Pavel Babica, Lola Bajard, et al.
Current Drug Metabolism|February 24, 2011
Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitorsMaria Pieri, Nadia Miraglia, Giuliano Polichetti, et al.
Lipids in Health and Disease|April 17, 2025
Lipid rafts: novel therapeutic targets for metabolic, neurodegenerative, oncological, and cardiovascular diseasesMohamad Warda, Samet Tekin, Mahmoud Gamal, et al.
Pageof 13